Symbols / GRCE $4.01 +1.52%
GRCE Chart
About
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 60.85M |
| Enterprise Value | 42.45M | Income | -5.98M | Sales | — |
| Book/sh | 4.19 | Cash/sh | 1.21 | Dividend Yield | — |
| Payout | 0.00% | Employees | 6 | IPO | — |
| P/E | — | Forward P/E | -6.19 | PEG | — |
| P/S | — | P/B | 0.96 | P/C | — |
| EV/EBITDA | -3.78 | EV/Sales | — | Quick Ratio | 14.56 |
| Current Ratio | 14.96 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.31 | EPS next Y | -0.65 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-12 08:00 | ROA | -10.84% |
| ROE | -10.22% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 14.13M |
| Shs Float | 9.77M | Short Float | 0.50% | Short Ratio | 0.90 |
| Short Interest | — | 52W High | 4.30 | 52W Low | 1.75 |
| Beta | 0.76 | Avg Volume | 128.97K | Volume | 259.22K |
| Target Price | $11.56 | Recom | Strong_buy | Prev Close | $3.95 |
| Price | $4.01 | Change | 1.52% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.56
Mean price target
2. Current target
$4.01
Latest analyst target
3. DCF / Fair value
$-8.43
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.01
Low
$11.04
High
$12.09
Mean
$11.56
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-02-18 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
- Grace Therapeutics, Inc. (NASDAQ:GRCE) Short Interest Update - MarketBeat Wed, 11 Mar 2026 03
- April 23 FDA target date set for Grace’s GTx-104 aSAH drug - Stock Titan hu, 12 Feb 2026 08
- What sentiment indicators say about GRCE stock - 2025 Sector Review & Reliable Intraday Trade Plans - Naître et grandir Sat, 07 Mar 2026 02
- We Think Grace Therapeutics (NASDAQ:GRCE) Needs To Drive Business Growth Carefully - Yahoo Finance ue, 23 Sep 2025 07
- Companies Like Grace Therapeutics (NASDAQ:GRCE) Are In A Position To Invest In Growth - simplywall.st hu, 19 Feb 2026 08
- Grace Therapeutics, Inc. (NASDAQ:GRCE) Is Expected To Breakeven In The Near Future - Yahoo Finance ue, 24 Jun 2025 07
- Grace (NASDAQ: GRCE) secures $4.0M as FDA accepts NDA for GTx-104; PDUFA date set - Stock Titan hu, 23 Oct 2025 07
- Grace Therapeutics Q3 2026 Financial Results and Business Update - TradingView hu, 12 Feb 2026 08
- Grace Therapeutics, Inc. (NASDAQ:GRCE) Short Interest Update - MarketBeat Sat, 28 Feb 2026 08
- Grace Therapeutics (GRCE) Advances Towards FDA Review with Promi - GuruFocus hu, 12 Feb 2026 19
- Trend Review: Is GRCE a stock for growth or value investors - Options Play & Daily Stock Momentum Reports - baoquankhu1.vn Fri, 06 Mar 2026 21
- Grace: Fiscal Q3 Earnings Snapshot - Barchart.com hu, 12 Feb 2026 08
- Grace Therapeutics, Inc. (NASDAQ:GRCE): When Will It Breakeven? - simplywall.st ue, 10 Jun 2025 07
- Grace Therapeutics Secures $30M Funding After Phase 3 Success, FDA Filing Set for Novel Hemorrhage Drug - Stock Titan Mon, 23 Jun 2025 07
- Grace Therapeutics Announces Financing of $30 Million - citybiz Mon, 10 Feb 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 147275 | 499998 | — | Acquisition carried out privately at price 3.40 per share. | Kavuru (Vimal) | Director of Issuer | — | 2025-02-11 00:00:00 | I |
Financials
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 802.17K | -527.36K | -6.24M | 287.81K |
| TaxRateForCalcs | 0.25 | 0.12 | 0.18 | 0.06 |
| NormalizedEBITDA | -19.87M | -7.10M | 15.85M | -19.99M |
| TotalUnusualItems | 3.20M | -4.23M | -33.97M | 4.65M |
| TotalUnusualItemsExcludingGoodwill | 3.20M | -4.23M | -33.97M | 4.65M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -9.57M | -12.85M | -42.43M | -9.82M |
| ReconciledDepreciation | 7.00K | 11.00K | 124.00K | 0.00 |
| ReconciledCostOfRevenue | 0.00 | 76.00K | ||
| EBITDA | -16.67M | -11.33M | -18.12M | -15.34M |
| EBIT | -16.68M | -11.37M | -18.25M | -15.34M |
| NetInterestIncome | 711.00K | 911.00K | 246.00K | 77.00K |
| InterestExpense | 0.00 | |||
| InterestIncome | 711.00K | 911.00K | 246.00K | 77.00K |
| NormalizedIncome | -11.97M | -9.15M | -14.70M | -14.18M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -9.57M | -12.85M | -42.43M | -9.82M |
| TotalExpenses | 16.68M | 11.37M | 18.25M | 15.34M |
| TotalOperatingIncomeAsReported | -16.68M | -12.85M | -52.16M | -15.59M |
| DilutedAverageShares | 12.09M | 9.53M | 7.44M | 6.14M |
| BasicAverageShares | 12.09M | 9.53M | 7.44M | 6.14M |
| DilutedEPS | -0.79 | -1.35 | -5.71 | -1.62 |
| BasicEPS | -0.79 | -1.35 | -5.71 | -1.62 |
| DilutedNIAvailtoComStockholders | -9.57M | -12.85M | -42.43M | -9.82M |
| NetIncomeCommonStockholders | -9.57M | -12.85M | -42.43M | -9.82M |
| NetIncome | -9.57M | -12.85M | -42.43M | -9.82M |
| NetIncomeIncludingNoncontrollingInterests | -9.57M | -12.85M | -42.43M | -9.82M |
| NetIncomeContinuousOperations | -9.57M | -12.85M | -42.43M | -9.82M |
| TaxProvision | -3.20M | -1.83M | -9.54M | -648.00K |
| PretaxIncome | -12.77M | -14.69M | -51.97M | -10.47M |
| OtherIncomeExpense | 3.20M | -4.23M | -33.97M | 4.80M |
| OtherNonOperatingIncomeExpenses | 147.00K | |||
| SpecialIncomeCharges | 0.00 | -1.49M | -33.91M | -249.00K |
| WriteOff | 0.00 | 400.00K | 249.00K | 413.00K |
| ImpairmentOfCapitalAssets | 0.00 | 33.51M | 0.00 | 5.29M |
| RestructuringAndMergernAcquisition | 0.00 | 1.49M | 0.00 | |
| GainOnSaleOfSecurity | 3.20M | -2.74M | -62.00K | 4.90M |
| NetNonOperatingInterestIncomeExpense | 711.00K | 911.00K | 246.00K | 77.00K |
| TotalOtherFinanceCost | -147.00K | 264.00K | ||
| InterestExpenseNonOperating | 0.00 | |||
| InterestIncomeNonOperating | 711.00K | 911.00K | 246.00K | 77.00K |
| OperatingIncome | -16.68M | -11.37M | -18.25M | -15.34M |
| OperatingExpense | 16.68M | 11.37M | 18.25M | 15.34M |
| DepreciationAmortizationDepletionIncomeStatement | 7.00K | 40.00K | 63.00K | 0.00 |
| DepreciationAndAmortizationInIncomeStatement | 7.00K | 40.00K | 63.00K | 0.00 |
| DepreciationIncomeStatement | 7.00K | 40.00K | 63.00K | 0.00 |
| ResearchAndDevelopment | 9.51M | 4.68M | 9.97M | 5.56M |
| SellingGeneralAndAdministration | 7.16M | 6.64M | 8.21M | 9.78M |
| SellingAndMarketingExpense | 194.00K | 136.00K | 116.00K | 1.14M |
| GeneralAndAdministrativeExpense | 7.16M | 6.64M | 8.08M | 9.66M |
| OtherGandA | 4.62M | 4.75M | 4.07M | 6.76M |
| SalariesAndWages | 2.54M | 1.90M | 4.01M | 2.91M |
| GrossProfit | 0.00 | 120.00K | ||
| CostOfRevenue | 0.00 | 76.00K | ||
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 13.72M | 9.40M | 7.44M | 7.38M |
| ShareIssued | 13.72M | 9.40M | 7.44M | 7.38M |
| TotalDebt | 0.00 | 485.00K | 295.00K | 86.00K |
| TangibleBookValue | 17.34M | 12.48M | 18.69M | 25.50M |
| InvestedCapital | 66.61M | 61.74M | 67.95M | 108.27M |
| WorkingCapital | 20.78M | 22.33M | 25.88M | 42.02M |
| NetTangibleAssets | 17.34M | 12.48M | 18.69M | 25.50M |
| CapitalLeaseObligations | 0.00 | 485.00K | 295.00K | 86.00K |
| CommonStockEquity | 66.61M | 61.74M | 67.95M | 108.27M |
| TotalCapitalization | 66.61M | 61.74M | 67.95M | 108.27M |
| TotalEquityGrossMinorityInterest | 66.61M | 61.74M | 67.95M | 108.27M |
| StockholdersEquity | 66.61M | 61.74M | 67.95M | 108.27M |
| GainsLossesNotAffectingRetainedEarnings | -6.04M | -6.04M | -6.04M | -6.04M |
| OtherEquityAdjustments | -6.04M | -6.04M | -6.04M | -6.04M |
| RetainedEarnings | -220.69M | -211.12M | -198.27M | -155.84M |
| AdditionalPaidInCapital | 293.33M | 278.90M | 13.96M | 12.15M |
| CapitalStock | 1.00K | 1.00K | 258.29M | 257.99M |
| CommonStock | 1.00K | 1.00K | 258.29M | 257.99M |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 5.38M | 11.56M | 11.17M | 20.35M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 3.45M | 9.87M | 7.76M | 17.09M |
| DerivativeProductLiabilities | 1.14M | 4.36M | 0.00 | 10.00K |
| NonCurrentDeferredLiabilities | 2.31M | 5.51M | 7.35M | 16.89M |
| NonCurrentDeferredTaxesLiabilities | 2.31M | 5.51M | 7.35M | 16.89M |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 410.00K | 191.00K | 0.00 |
| LongTermCapitalLeaseObligation | 0.00 | 410.00K | 191.00K | 0.00 |
| CurrentLiabilities | 1.93M | 1.68M | 3.41M | 3.26M |
| CurrentDebtAndCapitalLeaseObligation | 75.00K | 104.00K | 86.00K | |
| CurrentCapitalLeaseObligation | 0.00 | 75.00K | 104.00K | 86.00K |
| PayablesAndAccruedExpenses | 1.93M | 1.68M | 3.34M | 3.16M |
| CurrentAccruedExpenses | 668.00K | 176.00K | 946.00K | 296.00K |
| Payables | 1.26M | 1.51M | 2.39M | 2.86M |
| OtherPayable | 661.00K | 501.00K | 1.15M | 1.18M |
| AccountsPayable | 601.00K | 1.01M | 1.24M | 1.68M |
| TotalAssets | 71.99M | 73.30M | 79.12M | 128.62M |
| TotalNonCurrentAssets | 49.28M | 49.29M | 49.83M | 83.34M |
| GoodwillAndOtherIntangibleAssets | 49.27M | 49.27M | 49.27M | 82.77M |
| OtherIntangibleAssets | 41.13M | 41.13M | 41.13M | 69.81M |
| Goodwill | 8.14M | 8.14M | 8.14M | 12.96M |
| NetPPE | 15.00K | 24.00K | 567.00K | 565.00K |
| AccumulatedDepreciation | -11.00K | -698.00K | -609.00K | -446.00K |
| GrossPPE | 26.00K | 722.00K | 1.18M | 1.01M |
| OtherProperties | 571.00K | 1.05M | 900.00K | 86.00K |
| MachineryFurnitureEquipment | 26.00K | 151.00K | 127.00K | 111.00K |
| CurrentAssets | 22.71M | 24.01M | 29.29M | 45.28M |
| AssetsHeldForSaleCurrent | 0.00 | 352.00K | 768.00K | |
| CurrentDeferredAssets | 0.00 | |||
| PrepaidAssets | 453.00K | 283.00K | 598.00K | 720.00K |
| Receivables | 126.00K | 722.00K | 802.00K | 548.00K |
| OtherReceivables | 20.00K | 391.00K | 412.00K | 353.00K |
| TaxesReceivable | 106.00K | 316.00K | 338.00K | 184.00K |
| AccruedInterestReceivable | 0.00 | 15.00K | 52.00K | 11.00K |
| CashCashEquivalentsAndShortTermInvestments | 22.13M | 23.00M | 27.89M | 43.66M |
| OtherShortTermInvestments | 0.00 | 15.00K | 13.32M | 9.79M |
| CashAndCashEquivalents | 22.13M | 23.00M | 27.88M | 30.34M |
| CashEquivalents | 12.54M | |||
| CashFinancial | 27.88M | 30.34M | 38.41M |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| FreeCashFlow | -14.90M | -12.36M | -15.93M | -17.23M |
| RepaymentOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 15.00M | 7.50M | 304.00K | 0.00 |
| CapitalExpenditure | -22.00K | -17.00K | -69.00K | |
| EndCashPosition | 22.13M | 23.00M | 27.88M | 30.34M |
| BeginningCashPosition | 23.00M | 27.88M | 30.34M | 50.94M |
| EffectOfExchangeRateChanges | 0.00 | -8.00K | 153.00K | 1.39M |
| ChangesInCash | -872.00K | -4.87M | -2.46M | -20.76M |
| FinancingCashFlow | 14.03M | 7.36M | 304.00K | 0.00 |
| CashFlowFromContinuingFinancingActivities | 14.03M | 7.36M | 304.00K | 0.00 |
| NetOtherFinancingCharges | -967.00K | -162.00K | -143.00K | |
| ProceedsFromStockOptionExercised | 0.00 | 21.00K | 0.00 | 0.00 |
| NetCommonStockIssuance | 15.00M | 7.50M | 304.00K | 0.00 |
| CommonStockIssuance | 15.00M | 7.50M | 304.00K | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtPayments | 0.00 | |||
| InvestingCashFlow | 0.00 | 104.00K | 13.15M | -3.52M |
| CashFlowFromContinuingInvestingActivities | 0.00 | 104.00K | 13.15M | -3.52M |
| NetInvestmentPurchaseAndSale | 0.00 | 15.00K | 13.17M | -3.52M |
| SaleOfInvestment | 15.00K | 6.57M | 18.18M | 31.41M |
| PurchaseOfInvestment | -15.00K | -6.55M | -5.01M | -34.93M |
| NetPPEPurchaseAndSale | 0.00 | 89.00K | -17.00K | 0.00 |
| SaleOfPPE | 0.00 | 111.00K | 0.00 | |
| PurchaseOfPPE | 0.00 | -22.00K | -17.00K | 0.00 |
| OperatingCashFlow | -14.90M | -12.33M | -15.91M | -17.23M |
| CashFlowFromContinuingOperatingActivities | -14.90M | -12.33M | -15.91M | -17.23M |
| ChangeInWorkingCapital | 342.00K | -1.28M | 181.00K | -2.79M |
| ChangeInOtherCurrentAssets | 0.00 | -23.00K | 0.00 | 0.00 |
| ChangeInPayablesAndAccruedExpense | -84.00K | -1.65M | 411.00K | -2.39M |
| ChangeInPayable | -84.00K | -1.65M | 411.00K | -2.39M |
| ChangeInPrepaidAssets | -170.00K | 315.00K | 72.00K | -380.00K |
| ChangeInReceivables | 596.00K | 80.00K | -302.00K | -18.00K |
| OtherNonCashItems | 264.00K | |||
| StockBasedCompensation | 730.00K | 913.00K | 1.81M | 1.34M |
| AssetImpairmentCharge | 0.00 | 33.91M | 249.00K | 5.70M |
| DeferredTax | -3.20M | -1.83M | -9.54M | -648.00K |
| DeferredIncomeTax | -3.20M | -1.83M | -9.54M | -648.00K |
| DepreciationAmortizationDepletion | 7.00K | 11.00K | 124.00K | 0.00 |
| DepreciationAndAmortization | 7.00K | 11.00K | 124.00K | 0.00 |
| AmortizationCashFlow | 0.00 | 781.00K | ||
| AmortizationOfIntangibles | 0.00 | 781.00K | ||
| Depreciation | 7.00K | 11.00K | 124.00K | 0.00 |
| OperatingGainsLosses | -3.22M | 2.71M | 34.00K | -5.57M |
| GainLossOnInvestmentSecurities | -3.22M | 2.73M | -10.00K | -5.20M |
| NetForeignCurrencyExchangeGainLoss | 0.00 | 5.00K | -370.00K | 814.00K |
| GainLossOnSaleOfPPE | 0.00 | -59.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -9.57M | -12.85M | -42.43M | -9.82M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for GRCE
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|